SC
OCUL icon

Scotia Capital’s Ocular Therapeutix OCUL Stock Holding History

Scotia Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Buy
+13,337
New +$127K ﹤0.01% 881
2024
Q4 		– Sell
-12,138
Closed -$106K – 901
2024
Q3 		$106K Buy
+12,138
New +$100K ﹤0.01% 803

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Scotia Capital's OCUL Position: Q1 2026 in Review

Scotia Capital opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 13,337 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #881 among its holdings. This is a return to the name: Scotia Capital previously reported a position in OCUL as recently as Q3 2024.

Scotia Capital first reported a position in OCUL in Q3 2024 and has held it in 2 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Scotia Capital held 13,337 shares of Ocular Therapeutix worth $113K as of Q1 2026.
  • Ocular Therapeutix was a new Scotia Capital position in Q1 2026.
  • Ocular Therapeutix made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #881 holding.
  • Scotia Capital first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 2 quarters since.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.